

Online Resource 5

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy


Journal: Breast Cancer Research and Treatment

Authors: A.F. de Groot¹, E.J. Blok^{1,2}, A. Charehbili^{1,2}, C.C. Engels², V.T.H.B.M. Smit³, N.G. Dekker-Ensink², H. Putter⁴, E. Meershoek - Klein Kranenbarg², C.J.H. van de Velde², G.J. Liefers², J.W.R. Nortier¹, P.J.K. Kuppen², S.H. van der Burg¹, J.R. Kroep¹

Departments of Medical Oncology¹, Surgery², Pathology³, Statistics⁴, Leiden University Medical Center, Leiden, The Netherlands

Corresponding author: Judith R. Kroep, M.D., Ph.D. (j.r.kroep@lumc.nl)

Online Resource 5 Kaplan-Meier survival estimates based on HR status and based on CD8+ tumor infiltrate, stratified on HLA class 1 status



a Effect of HR status on DFS (hazard ratio 0.57, 95% CI 0.25-1.32, $p=0.19$) **b** Effect of CD8+ tumor infiltrate on DFS in patients with HR- disease with HLA class 1 expression (hazard ratio 0.56, 95% CI 0.12-2.49, $p=0.44$; Kaplan-Meier survival estimate and Cox regression analysis not possible for HLA class 1 loss or downregulation due to small numbers; p for interaction 0.99) **c** Effect of CD8+ tumor infiltrate on DFS in patients with HR+ disease with HLA class 1 loss or downregulation (hazard ratio 7.51, 95% CI 0.87-65.20, $p=0.07$) **d** Effect of CD8+ tumor infiltrate on DFS in patients with HR+ disease with HLA class 1 expression (hazard ratio 0.32, 95% CI 0.08-1.24, $p=0.098$). P for interaction 0.01. P -values in figure represent log-rank survival test